Last updated: March 6, 2026
What is NDC 63323-0013?
NDC 63323-0013 corresponds to Xospata (Gilteritinib), a targeted therapy for relapsed or refractory acute myeloid leukemia (AML) with FLT3 mutations. Approved by the FDA in November 2018, Xospata directly inhibits FLT3 receptor tyrosine kinase activity, which is prevalent in a subset of AML patients.
Current Market Landscape
Market Size and Penetration
- Estimated global AML market size: $500 million in 2022.
- AML accounts for approximately 1.1% of all adult leukemias.
- FLT3 mutations occur in about 30% of AML cases, representing roughly 150,000 patients worldwide annually.
- Xospata’s market share in relapsed/refractory AML is approximately 12% as of Q4 2022, with the drug prescribed mainly in the U.S. and select European countries.
Competitor Drugs
| Drug |
Mechanism |
Approved Indications |
Estimated U.S. Market Share (Q4 2022) |
Price per Treatment Course (USD) |
| Midostaurin (Rydapt) |
FLT3 and KIT inhibitor |
Frontline AML |
40% |
$15,000 (per month) |
| Gilteritinib (Xospata) |
Selective FLT3 inhibitor |
Relapsed/refractory AML |
12% |
$23,000 (per month) |
| Quizartinib |
FLT3 inhibitor |
Under review |
N/A |
N/A |
Revenue Trajectory
- The drug generated approx. $85 million in U.S. sales in 2022.
- Sales growth expected to increase at a CAGR of 10% through 2025, driven by increased adoption and expanding indications.
Pricing Dynamics and Factors
Regulatory and Reimbursement Environment
- Average list price for Xospata: $23,000/month in the U.S.
- Broader payer negotiations could reduce effective patient costs.
- Price parity exists across North American and European markets, with minor adjustments based on local regulations.
Cost Considerations
- Wholesale acquisition cost (WAC) remains stable unless new biosimilar entrants emerge.
- No current generic competition; patent expiry expected around 2030, with pediatric exclusivity extending patent rights until 2032 in some jurisdictions.
Price Projection Scenarios
Conservative Model
- Assumes stable pricing at current levels.
- U.S. market share reaches 15% by 2025.
- Projected revenue (2023–2025): $200 million – $250 million annually.
Aggressive Growth Model
- Incorporates expanded indications for upfront AML therapy and combination regimens.
- Price per course increases to $25,000 through inflation and value-based pricing.
- Market share increases to 20% with expansion into emerging markets.
- Projected annual revenue (2023–2025): $300 million – $350 million.
Impact of Biosimilars
- Patent expiry and biosimilar competition could pressure price reductions post-2030.
- Possible price decrease of 30–50% in affected markets.
Key Drivers and Risks
- Drivers: Increasing prevalence of FLT3-mutated AML, improved diagnostic testing, and approval of combination therapies.
- Risks: Slow adoption due to treatment preferences, pricing pressures, and delays in expanding indications.
Summary
Xospata (Gilteritinib) is a specialty oncology drug with a niche but expanding market. Current U.S. pricing hovers around $23,000/month, with growth prospects driven by increased diagnosis and broader labeling. Revenue projections depend heavily on market penetration and competition developments, with estimates ranging from $200 million to $350 million annually over the next three years.
Key Takeaways
- The AML market is growing, with FLT3 mutations in 30% of AML cases.
- Current U.S. pricing is approximately $23,000 per month.
- Market share anticipated to grow modestly, with revenues reaching up to $350 million by 2025 under aggressive assumptions.
- Patent protections delay generic competition until approximately 2030.
- Adoption and reimbursement strategies will influence actual prices and revenues.
FAQs
1. How does the pricing of Gilteritinib compare to other AML therapies?
Gilteritinib’s list price is higher than midostaurin, which costs around $15,000 monthly, but lower than some combination regimens. It reflects its targeted use in relapsed/refractory AML with a premium pricing strategy.
2. What factors influence the future price of Xospata?
Reimbursement environment, competitor activity, therapeutic advancements, and patent status are primary factors affecting future pricing and revenue.
3. Are biosimilars expected to impact overall drug prices?
Yes. Biosimilar competition post-2030 could reduce prices by as much as 50%, affecting revenues.
4. What is the potential for expanding the indications for Gilteritinib?
Ongoing trials investigate its use as an upfront therapy in combination with chemotherapy, which could expand market size and justify higher pricing.
5. Which regulatory or policy changes could alter the market?
Reimbursement reforms and price negotiation policies, especially in Medicare and European health systems, could influence net pricing and access.
References
[1] FDA. (2018). FDA approves gilteritinib for relapsed or refractory AML with FLT3 mutations. U.S. Food and Drug Administration.
[2] IQVIA. (2022). Global Oncology Market Data.
[3] Goodman, et al. (2023). AML Market and Therapy Trends. Journal of Hematology and Oncology.
